Botox USA vs Korea comes down to three things you can check: which toxin brand goes into the syringe, who injects it, and who looks after the result once you are home. Botox by Allergan and Xeomin by Merz are approved in both countries, and Nabota by Daewoong is sold in the US as Jeuveau. Several other Korean-made brands are licensed in Korea but not approved for sale in the US. A session itself takes minutes, with small bumps or redness that usually settle the same day, and the effect builds over several days. This page sets out product approval, unit counts, injector rules and aftercare so a Busan visit can be planned around them.
Guide
Which toxin brands each regulator has approved
The cleanest comparison is the product label. The US Food and Drug Administration and Korea's Ministry of Food and Drug Safety approve brands separately, so a Busan menu can mix brands your home injector uses with brands never sold in America.
If keeping the same product on both sides of the Pacific matters to you, ask for the brand by name and ask to see the sealed vial opened. A menu that says Botox for every line does not tell you which product it means.
| Brand | Maker | Active ingredient | US status | Status in Korea |
|---|---|---|---|---|
| Botox | Allergan (AbbVie) | onabotulinumtoxinA | FDA approved | Approved, listed as the imported original |
| Xeomin | Merz | incobotulinumtoxinA | FDA approved | Approved, listed as an imported option |
| Nabota | Daewoong | prabotulinumtoxinA | FDA approved under the name Jeuveau | Approved under the name Nabota |
| Coretox, Meditoxin, Innotox | Medytox | botulinum toxin type A | Not approved for US sale | Approved |
| Hutox, Liztox, Hi-tox | Huons, Huons BioPharma, Korea BMI | botulinum toxin type A | Not approved for US sale | Approved |
Guide
Why a unit count only travels within one brand
A unit count on a US chart is only meaningful next to the brand name. Units are measured by each manufacturer's own potency test, so they translate cleanly only where a trial has compared the products directly.
One such trial is behind the Xeomin and Botox pairing. In a 2010 randomized, rater- and patient-blind Phase III trial in Dermatologic Surgery, Sattler and colleagues gave 381 patients 24 units of either incobotulinumtoxinA or onabotulinumtoxinA for frown lines. At week four, independent raters found nearly identical response rates, confirming noninferiority, and both products were well tolerated.
AbobotulinumtoxinA, sold in the US as Dysport, is counted on a different scale. For Korean-made brands, ask the treating doctor how many units they plan per area and how that relates to your home record.
Guide
Who holds the syringe in each country
In the US, the rules on who may inject are set state by state, and in many states a trained nurse or physician assistant injects under a supervising physician. In Korea, toxin injection is a medical procedure carried out at a medical clinic, so the useful question is whether the doctor you consult is the one who injects.
Either way, ask about the same safeguards: an assessment of how your muscles move, marked injection points, a stated unit count per area, and written aftercare you can read.
Guide
Antibodies, repeat doses and switching brands
People who split treatments between two countries often switch brands without noticing. A small share of patients develop neutralizing antibodies, which can make later injections work less well.
A 2024 analysis in Plastic and Reconstructive Surgery by Rahman and colleagues pooled 14 randomized trials with 8,190 participants across five toxin products. Dose and treatment frequency were the main factors linked to antibody formation; incobotulinumtoxinA showed the lowest and abobotulinumtoxinA the highest likelihood.
The practical step is one record kept across both countries, and no short-interval top-ups in either.
- Brand and, if offered, the lot number from the vial
- Total units and units per area
- Date of treatment and date of any review visit
- Any side effect, however mild, and how long it lasted
Guide
Follow-up once you have flown back to the US
The biggest practical difference is distance. Clinics often invite patients back around two weeks after injections to check symmetry, and a visitor who flies home from Gimhae within days cannot attend. If you can, schedule toxin near the start of a Busan stay rather than on the last morning.
Before leaving, ask whether the clinic will advise by message if one brow sits higher, and whether your home injector will adjust work done with a brand they may not stock. Some prefer to wait until the full effect has settled.
Evidence
Research behind this page
- Noninferiority of IncobotulinumtoxinA, Free from Complexing Proteins, Compared with Another Botulinum Toxin Type A in the Treatment of Glabellar Frown LinesDermatologic Surgery · 2010 · doi:10.1111/j.1524-4725.2010.01706.x
In 381 patients, 24 units of incobotulinumtoxinA proved noninferior to 24 units of onabotulinumtoxinA for frown lines at week four.
- Predictive Modeling of Immunogenicity to Botulinum Toxin A Treatments for Glabellar LinesPlastic & Reconstructive Surgery · 2024 · doi:10.1097/prs.0000000000011748
Across 14 trials, antibody risk tracked mainly with dose and treatment frequency, and was lowest for incobotulinumtoxinA.
FAQ
Questions about Botox in Busan
Is Jeuveau the same product as Nabota?
Yes, Jeuveau is the US trade name for prabotulinumtoxinA made by Daewoong, which Korean clinics list as Nabota. The FDA approved it under the Jeuveau name for frown lines, while Korea's regulator licenses it as Nabota. If your US injector already uses Jeuveau, asking for Nabota in Busan keeps you on the same active ingredient, and your home record of units should carry over without conversion. Confirm the name on the vial before it is opened.
Is the Botox stocked in Korea a different formula from the American one?
Botox in a Korean clinic is the Allergan product with the same active ingredient, onabotulinumtoxinA, approved separately by Korea's Ministry of Food and Drug Safety. Packaging follows Korean rules, so the box can look unfamiliar even when the brand is the same. Confusion usually comes from menus that use the word Botox for every toxin. Ask whether the line you chose means the Allergan product or a Korean-made brand.
What should I do if an eyelid droops after I am back home?
See a doctor at home promptly, bring your treatment record, and send the Busan clinic a message describing what you notice. A drooping lid or brow happens when toxin affects a nearby muscle, and it usually fades as the effect wears off over weeks. Prescription eye drops can help some lid cases, which is why a local doctor matters. Knowing the brand and units injected lets them judge the likely course quickly.
Should my US doctor know about injections I had abroad?
Yes, tell your home doctor and injector about any toxin treatment abroad, with the brand, units and date. That record helps them space your next session, avoid stacking doses, and spot a reduced response early. It also matters for medical uses of toxin, such as migraine or muscle spasm care. A photo of the vial label and the clinic's written notes is usually enough.
Who should not plan toxin injections during a trip?
People who are pregnant or breastfeeding, have a neuromuscular disorder such as myasthenia gravis, or have an infection or active rash at the injection area should not be treated. Anyone who reacted badly to a toxin product before should share that history first. Those with an important event or photo shoot within a few days should also wait, because the effect builds gradually. Results vary from person to person.